<DOC>
	<DOC>NCT02930837</DOC>
	<brief_summary>To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke</brief_summary>
	<brief_title>Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Inclusion criteria: Age &gt;= 18 years at screening(visit 1A) but &lt;= 80 years Signed and dated written informed consent in accordance with good clinical practice and local legislation prior to admission to the trial Diagnosis of ischemic stroke with a measureable neurological deficit on National Institute of Health Stroke Scale (NIHSS) Thrombolytic therapy can be initiated within 3 to 4.5 hours of stroke onset Further inclusion criteria apply Exclusion criteria: Evidence of intracranial haemorrhage (ICH) on the (Computure Tomography) CT/(Magnetic Resonance Imaging)MRIscan or symptoms suggestive of subarachnoid haemorrhage, even if the CT/MRIscan is normal Acute bleeding diathesis Severe stroke as assessed clinically( e.g. National Institute of Health Stroke Scale&gt;25) and/ or imaging demonstrates multilobar infarction (hypodensity &gt;1/3 cerebral hemisphere) Severe uncontrolled arterial hypertension, e.g. systolic blood pressure&gt;185 mmHg or diastolic blood pressure&gt;110mmHg, or aggressive management (intravenous medication) necessary to reduce blood pressure to these limits Blood glucose &lt;50mg/ dL or &gt;400 mg/dL Any history of prior stroke in previous 3 months, or any history of prior stroke with concomitant diabetes Seizure at stroke onset Further exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>